Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer
The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.
Prostate Cancer
BIOLOGICAL: Dendritic Cells DCVAC/PCa
Safety evaluation of the second cycle of DCVAC, Safety evaluation of the second cycle of active cellular immunotherapy, which includes a second leukapheresis procedure, who after primary radical prostatectomy completed first cycle of active cellular immunotherapy in clinical trial SP003 without objective disease progression requiring additional anti-tumor therapy., 52 weeks
Time to Prostate Specific Antigen (PSA) Doubling Time, 52 weeks
Same as brief summary